St Jude's most recent trend suggests a bullish bias. One trading opportunity on St Jude is a Bull Put Spread using a strike $60.00 short put and a strike $50.00 long put offers a potential 5.26% return on risk over the next 25 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $60.00 by expiration. The full premium credit of $0.50 would be kept by the premium seller. The risk of $9.50 would be incurred if the stock dropped below the $50.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for St Jude is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for St Jude is bullish.
The RSI indicator is at 44.22 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for St Jude
Health care stocks hitting new highs
Mon, 27 Oct 2014 17:54:00 GMT
St. Jude Medical Receives FDA Approval of TactiCath Quartz Contact Force Ablation Catheter for Treatment of Atrial Fibrillation
Mon, 27 Oct 2014 12:12:00 GMT
noodls – TactiCath ablation catheter with contact-force measurement provides physicians with a new option for treating patients with atrial fibrillation ST. PAUL, Minn.–(BUSINESS WIRE)– St. Jude Medical, Inc. …
8:03 am St. Jude Medical receives FDA Approval of TactiCath Quartz Contact Force ablation catheter for treatment of Atrial Fibrillation
Mon, 27 Oct 2014 12:03:00 GMT
St. Jude Medical Receives FDA Approval of TactiCath Quartz Contact Force Ablation Catheter for Treatment of Atrial Fibrillation
Mon, 27 Oct 2014 12:00:00 GMT
Business Wire – St. Jude Medical, Inc. , a global medical device company, today announced U.S. Food and Drug Administration approval of its TactiCath™ Quartz irrigated ablation catheter, the company’s newest technology that gives physicians a real-time, objective measure of the force that the catheter applies to a patient’s heart wall during an ablation procedure.
Post-Earnings Analyst Review – St. Jude Medical
Wed, 22 Oct 2014 13:35:56 GMT
noodls – Editor Note: For more information about this release, please scroll to bottom. … This is an abstract of the original noodl. To continue reading this document, click here for the original version.
Related Posts
Also on Market Tamer…
Follow Us on Facebook